Cancer research is one of the most rigorous scientific endeavors of the 21st century. Bodies and personalities input time, effort and money into hundreds of projects seeking the same goal. Clay Siegall is a vigorous scientist and philanthropist who relishes the day cancer will be treatable. He owns and leads Seattle Genetics as the board chairman and chief executive officer. Under his leadership, Seattle has developed FDA-approved ADCs, such as the ADCETRIS. ADCETRIS earned an FDA approval in 2011 and is currently available in more than 65 nations. In 2015, Clay announced that the firm has initiatives to develop more ADCs targeted to treat cancer.

Young Clay Siegall watched his father have cancer for five years, until his demise. He resolved to be part of the cancer research movement by enrolling in George Washington University to pursue a Doctorate in Genetics. After school, Clay joined Bristol-Meyers Pharmaceutical Institute and later branched away to set up Seattle Genetics. His strongest motivation is the need to improve cancer therapies, and finally breakthrough to find a cure. Clay is a seasoned entrepreneur, leader, and scientist who uses his skills to propel the firm.

Clay Siegall understands that one gains more knowledge and a keener perception of life with increasing age. Clay stated that while he was in his twenties, he thought he had a good grasp of life’s complexities. As he grew into his thirties, he realized just how much deeper life is. Currently, as he is in his forties, Clay maintains an open attitude that quickly picks up new perceptions. After leaving Bristol-Myers in 1997, he joined the National Cancer Institute and served for eight years. He is a member on the boards of Washington Roundtable and Biopharmaceuticals. Clay Siegall has earned a couple of awards for his career, such as the 2012 Pacific Northwest Young $ Ernst Entrepreneur Award, and the 2013 Alumnus of the Year award from his former school, the University of Maryland. He has documented his findings in more than 70 pieces and is the holder of 15 patents. Clay joined the University of Maryland to pursue a Bachelor in Zoology before joining George Washington.